Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.64 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.64 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.64 |
| ▸ | THRA | P10827 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523155 | 0.84 | EGLN1 (0.71) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL3781066 | 0.83 | EGLN1 (0.67) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL522718 | 0.82 | EGLN1 (0.69) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL523235 | 0.79 | EGLN1 (0.70) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL29390250 | 0.79 | EGLN1 (1.00) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL522744 | 0.79 | EGLN1 (1.00) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL12502836 | 0.78 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL522936 | 0.77 | EGLN1 (0.57) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL522881 | 0.76 | EGLN1 (0.63) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL967123 | 0.76 | EGLN1 (0.54) | EGLN1FTOBBOX1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276477-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885FTO 1896/4885BBOX1 2424/4885 |
| US-20060276477-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885FTO 1896/4885BBOX1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.